Ligand id: 4128

Name: amantidine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 26.02
Molecular weight 151.14
XLogP 2.31
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Amantidine has historically been used as an antiviral agent to treat influenza, but as the flu virus has become resistant to amantadine this useis no longer recommended.
In August 2017, the US FDA approved Gocovri®, and extended release, high dose formulation of amantidine for the treatment of dyskinesia in Parkinson's disease (PD), for patients already receiving levodopa-based therapy, irrespective of whether or not they are receiving concomitant dopaminergic medications. Clinical trial results showed that Gocovri® reduced both dyskinesia and 'off' time in levodopa treated PD patients [2]. This first PD approval was followed in February 2018 with FDA approval of Osmolex ER (another extended release formulation of amantidine) for the treatment of PD and for the treatment of drug-induced extrapyramidal reactions.
Mechanism Of Action and Pharmacodynamic Effects
Amantidine's MMOA in the treatment of Parkinson's symptoms arises from its multifunctional activity. These actions include, antagonism of the NMDA type glutamate receptor, stimulation of increased dopamine release, and inhibition of dopamine reuptake.